Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
51 hedge funds and large institutions have $134M invested in Regulus Therapeutics in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 3 closing their positions.
1,017% more capital inflows, than outflows
Capital inflows: $60.9M | Capital outflows: $5.45M
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
31% more funds holding
Funds holding: 39 → 51 (+12)
13.29% more ownership
Funds ownership: 20.71% → 34% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.8M |
| 2 |
HealthCor Management
New York
|
+$9.6M |
| 3 |
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$8.85M |
| 4 |
Jennison Associates
New York
|
+$3.52M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Emerald Advisers
Leola,
Pennsylvania
|
-$2.4M |
| 2 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.35M |
| 3 |
Morgan Stanley
New York
|
-$393K |
| 4 |
Spark Investment Management
New York
|
-$347K |
| 5 |
BVF Inc
San Francisco,
California
|
-$322K |
RGLS Hedge Fund Activity: Q3 2013 in Review
51 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2013, worth a combined $134M — up 59% from $84M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RGLS positions and 3 closed out — a net gain of 12 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $21.8M. The largest seller was Emerald Advisers, cutting an estimated $2.4M.
- 51 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2013, up from 39 in Q2 2013.
- Funds reported $134M of Regulus Therapeutics stock for Q3 2013, up 59% quarter-over-quarter.
- 15 funds opened new Regulus Therapeutics positions in Q3 2013 and 3 closed out, a net change of +12 holders.
- The largest Regulus Therapeutics buyer in Q3 2013 was Fidelity Investments, an estimated $21.8M added.
- The largest Regulus Therapeutics seller in Q3 2013 was Emerald Advisers, an estimated $2.4M sold.
Based on aggregated 13F filings for Q3 2013.